Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Edwards Lifesciences Corp.

Share:
Related EW
Mid-Afternoon Market Update: Fang Holdings Drops Following Q3 Results; Recro Pharma Shares Surge
Mid-Day Market Update: Crude Oil Up Over 2%; PhaseRx Shares Spike Higher
Boston Scientific Acquisition Eyes Rivals Edwards, Medtronic (Investor's Business Daily)

In a report published Friday, Jefferies & Company reiterated its Buy rating on Edwards Lifesciences Corp. (NYSE: EW), and raised its price target from $115.00 to $125.00.

Jefferies noted, “We published two physician surveys on transcatheter aortic valve replacement (TAVR), one of early adopters and the other of current non-users. Based on the results, which show strong and sustainable procedure growth, we are increasing our forecasts and target. We continue to rate EW shares Buy.”

Edwards Lifesciences Corp. closed on Thursday at $102.88.

Latest Ratings for EW

DateFirmActionFromTo
Nov 2016Northland SecuritiesUpgradesMarket PerformOutperform
Jul 2016JMP SecuritiesMaintainsMarket Outperform
Jul 2016Bank of AmericaUpgradesNeutralBuy

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!